Quiz Symposium 4. The 2021 WHO CNS tumor classification : The Fifth!

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

QUIZ QUESTIONS AS SUBMITTED BY THE INVITED SPEAKERS

1) ‘NOW’ in cIMPACT-NOW initially meant: *

1 point

A) Not Official WHO

B) The members of the consortium would like to see impact of their recommendations a.s.a.p.

C) Both A and B

D) Neither A nor B

2) Salient recommendations in the cIMPACT-NOW updates include *

1 point

A) Using TERT promoter mutation as criterion for WHO CNS grade 4 in IDH-wildtype diffuse gliomas (correct answer)

B) Using homozygous CDKN2A/B deletion as criterion for high-grade malignancy in oligodendroglioma, IDH-mutant and 1p/19q-codeleted

C) Using KIAA1549-BRAF fusion as criterion for pilocytic astrocytoma

D) All of the above

3) In the absence of microvascular proliferation and necrosis, an IDH-wildtype diffuse astrocytoma should be classified as glioblastoma, IDH-wildtype, WHO grade 4 according to the new WHO classification 2021 when the following molecular alteration is present: *

1 point

A) 1p/19q codeletion

B) BRAF V600E mutation

C) EGFR gene amplification

D) MGMT promoter methylation

4) Which of the following statements is considered as a new diagnostic criterion in the WHO classification 2021? *

1 point

A) Homozygous CDKN2/B deletion is a molecular marker of WHO grade 4 in an IDH-mutant astrocytoma

B) Homozygous CDKN2/B deletion excludes an IDH-wildtype glioblastoma

C) H3.3 G34 mutation is a molecular marker of diffuse midline gliomas

D) Pleomorphic low-grade neuroepithelial tumor of the young (PLNTY) is molecularly characterized by MYB-QKI fusion genes

Submit

Clear form

This form was created inside of Euro-CNS. Report Abuse

Forms